Drug Shows Potential to Combat Exaggerated Inflammation Linked to COVID-19

According to Zamboni, the anti-inflammatory effects of niclosamide observed in the study were due to inhibition of an immune system mechanism known as the inflammasome, a protein complex present in the interior of defense cells. When this cellular machinery is activated, pro-inflammatory molecules called cytokines are produced to warn the immune system that more defense cells need to be sent to the site of the infection.

Previous research by the FMRP-USP group showed that inflammasomes in severe COVID-19 patients are typically more activated than normal and remain so even after the virus has been eliminated from the organism, causing an exaggerated systemic inflammatory response known as a cytokine storm that injures the lungs and other organs (more at: agencia.fapesp.br/39411/).

Zamboni stressed, however, that niclosamide should not be used prophylactically to prevent exacerbated inflammation. “A little inflammation is important to combat infection by pathogenic microorganisms,” he said. “Exaggerated inflammation is the problem, as is often the case in severe COVID-19. We’re not recommending prophylactic use of the drug, since this could even hinder a recovery by mild or moderate COVID-19 patients.”

Niclosamide has been on the market for many years and is mainly prescribed to treat taeniasis (tapeworm infection). It has recently aroused interest among researchers due to claims of potential antiviral action.

According to the authors of the Science Advances article, niclosamide promotes autophagy, a vital process that removes and recycles unwanted or damaged molecules from the body’s cells. When this process of autophagic cell cleansing is induced, old organelles are destroyed, cellular components are recycled and inflammasomes are deactivated. The process also inhibits replication of SARS-CoV-2 inside cells.

The researchers began the study by screening 2,560 compounds, many of which are already used in humans, in a search for substances capable of inflammasome modulation. This involved infecting human defense cells in vitro with Legionella, a bacterium known for inflammasome activation.

After selecting the three most promising drugs, the researchers tested them on mice infected with SARS-CoV-2 and white blood cells from COVID-19 patients. They also tested the effects of these drugs on macrophages and monocytes, front-line immune cells intensely involved in COVID-related inflammasomes. Niclosamide produced the best results.

To investigate its antiviral action, the researchers tested it on monocytes infected in vitro with SARS-CoV-2. “Niclosamide’s antiviral action was already known. Indeed, phase 1 clinical trials involving treatment of COVID-19 patients with the drug are under way right now. Our discovery that it induces autophagy and inhibits inflammasomes offers additional information on the immunomodulatory functions of this highly promising drug,” Zamboni said.

“The study focused on COVID-19, but in theory niclosamide should also promote inflammasome inhibition in these other cases. Our results point to numerous other research possibilities,” Zamboni said.

Source: Eurekalert